Literature DB >> 19845751

Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack.

Y Okada1, K Shibazaki, K Kimura, Y Iguchi, T Miki.   

Abstract

BACKGROUND AND
PURPOSE: We investigated whether the brain natriuretic peptide (BNP) level can serve as a predictive biological marker of delayed atrial fibrillation (AF).
METHODS: Two hundred and thirty seven consecutive patients admitted to our institution with acute ischaemic stroke or transient ischaemic attack (TIA) within 24 h of onset were enrolled. The patients were classified according to the presence or absence of AF upon admission [AF and sinus rhythm (SR) groups]. The SR group was subdivided based on the development of AF after admission (new- and non-AF groups). We compared the characteristics between the AF and SR groups, and between the new- and non-AF groups. The factors associated with new-AF were investigated by multivariate logistic regression analysis.
RESULTS: Amongst the enrolled patients, 72 (30.4%) had AF upon admission (AF group), and 13 (5.5%) developed AF thereafter (new-AF group). The plasma BNP level was significantly higher in the AF, than in the SR group (401.7 vs. 92.1 pg/ml, P < 0.001). Moreover, the plasma BNP level was significantly higher in the new-, than in the non-AF group (184.7 vs. 84.1 pg/ml, P < 0.001). The optimal cutoff BNP level required to distinguish new-, from non-AF groups was 85.0 pg/ml, and the sensitivity and specificity was 83.3% and 76.2%, respectively. On multivariate logistic regression analysis, plasma BNP level >85.0 pg/ml (odds ratio, 7.20; 95% confidence interval, 1.71 to 30.43, P = 0.007) was an independent factor associated with new-AF.
CONCLUSION: High plasma BNP level should be a strong predictor of delayed AF after ischaemic stroke or TIA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19845751     DOI: 10.1111/j.1468-1331.2009.02813.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  7 in total

1.  Biomarker level improves the diagnosis of embolic source in ischemic stroke of unknown origin.

Authors:  E Santamarina; A Penalba; T García-Berrocoso; P Delgado; M Quintana; T González-Alujas; M Ribó; O Maisterra; C A Molina; A Evangelista; J Alvarez-Sabín; J Montaner
Journal:  J Neurol       Date:  2012-05-17       Impact factor: 4.849

Review 2.  Detection of atrial fibrillation and secondary stroke prevention using telemetry and ambulatory cardiac monitoring.

Authors:  Hooman Kamel; Wade S Smith
Journal:  Curr Atheroscler Rep       Date:  2011-08       Impact factor: 5.113

Review 3.  Paroxysmal Atrial Fibrillation: Novel Strategies for Monitoring and Implications for Treatment in Stroke.

Authors:  Scott B Silverman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-08

4.  Association of perioperative troponin and atrial fibrillation after coronary artery bypass grafting.

Authors:  Bas B Koolen; Joost A M Labout; Paul G H Mulder; Bastiaan M Gerritse; Tom A Rijpstra; Mohamed Bentala; Peter M J Rosseel; Nardo J M van der Meer
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-06-20

5.  Natriuretic peptides for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemia--the Find-AF study.

Authors:  Rolf Wachter; Rosine Lahno; Beatrice Haase; Mark Weber-Krüger; Joachim Seegers; Frank Edelmann; Janin Wohlfahrt; Götz Gelbrich; Anke Görlitz; Pawel Kermer; Dirk Vollmann; Gerd Hasenfuß; Klaus Gröschel; Raoul Stahrenberg
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

Review 6.  Brain-heart axis--Review Article.

Authors:  M M Manea; M Comsa; A Minca; D Dragos; Constantin Popa
Journal:  J Med Life       Date:  2015 Jul-Sep

7.  Paroxysmal Atrial Fibrillation in Cryptogenic Stroke Patients With Major-Vessel Occlusion.

Authors:  Ryosuke Doijiri; Hiroshi Yamagami; Masafumi Morimoto; Tomonori Iwata; Tetsuya Hashimoto; Kazutaka Sonoda; Hidekazu Yamazaki; Junpei Koge; Naoto Kimura; Kenichi Todo
Journal:  Front Neurol       Date:  2020-11-12       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.